Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Lung Cancer in Women, a Different Disease: Survival Differences by Sex in Turkey

  • Ulas, Arife (Department of Medical Oncology, Ankara Ataturk Training and Research Hospital) ;
  • Tokluoglu, Saadet (Ankara Oncology Teaching and Research Hospital) ;
  • Kos, Mehmet (Department of Internal Medicine, Faculty of Medicine, Duzce University) ;
  • Silay, Kamile (Department of Internal Medicine and Geriatrics, Faculty of Medicine, Yildirim Beyazit University) ;
  • Akinci, Sema (Department of Hematology, Ankara Ataturk Training and Research Hospital) ;
  • Oksuzoglu, Berna (Ankara Oncology Teaching and Research Hospital) ;
  • Alkis, Necati (Ankara Oncology Teaching and Research Hospital)
  • Published : 2015.02.25
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: In this study, we aimed to evaluate the effects of sex-based non-small cell lung cancer (NSCLC) varieties on survival rates. Materials and Methods: A retrospective study was performed in patients with NSCLC who were diagnosed by histological methods between the years 2000 and 2010. A chi-square test was used to compare variables. Overall survival (OS) was estimated by the Kaplan-Meier method. Results: Of the 844 patients, 117 (13.9%) were women and 727 (86.1%) were men. Adenocarcinoma was more common in women than in men (p<0.0001). There were more women non-smokers than men (p<0.0001). There was no statistically significant difference in ECOG PS, weight loss>10%, stage, LDH, albumin and treatment between women and men. Women younger than 65 years (17.0 vs 12.0 months; p=0.03), who had adenocarcinoma histology (15.0 vs 10.0 months; p=0.006) and who had a hemoglobin level ${\geq}12g/dL$ (18.0 vs 12.0 months; p=0.01) were found to have a better median OS rate than men. Median OS rates were found to be 13.0 months in females and 12.0 months in males (p=0.14). Among metastatic patients, the median OS was 11.0 months in females and 8.0 months in males (p=0.005). Among stage IIIB and stage IV patients who had first line platinum-based chemotherapy, the median OS was 17.0 months in women and 11.0 months in men (p=0.002). The response rate of chemotherapy was higher in women than in men (p=0.03). Conclusions: In our study, we found that survival duration is longer and chemotherapy response is better in women with NSCLC who do not have anemia or comorbidities and who are mostly non-smokers with adenocarcinomas. Further studies regarding the causes of these differences may provide clarity on this subject.

Keywords

References

  1. Albain KS, Crowley JJ, LeBlanc M, et al (1991). Survival determinants in extensive-stage non small-cell lung cancer: the Southwest oncology group experience. J Clin Oncol, 9, 1618-26.
  2. Babacan NA, Yucel B, Kilickap S, et al (2014). Lung cancer in women: a single institution experience with 50 patients. Asian Pac J Cancer Prev, 15, 151-4. https://doi.org/10.7314/APJCP.2014.15.1.151
  3. Bain C, Feskanich D, Speicer FE, et al (2004). Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst, 96, 826-34. https://doi.org/10.1093/jnci/djh143
  4. Batevik R, Grong K, Segadal L, Stangeland L (2005). The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer: a study of absolute and relative survival over 15 years. Lung Cancer, 47, 173-81. https://doi.org/10.1016/j.lungcan.2004.08.014
  5. Caldarella A, Crocetti E, Comin CE (2007). Gender differences in non-small cell lung cancer: a population-based study. Eur J Surg Oncol, 33, 763-8. https://doi.org/10.1016/j.ejso.2007.01.001
  6. Cerfolio RJ, Bryant AS, Scott E (2006). Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest, 130, 1796-802. https://doi.org/10.1378/chest.130.6.1796
  7. Chang JW, Asamura H, Kawachi R, Watanabe S (2009). Gender difference in survival of resected non-small cell lung cancer: histology-related phenomenon? J Thorac Cardiovasc Surg, 137, 807-12. https://doi.org/10.1016/j.jtcvs.2008.09.026
  8. Chlebowski RT, Schwartz AG, Wakelee H, et al (2009). Oestrogen plus progestin and lung cancer in postmenopausal women (women's health initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet, 374, 1243-51. https://doi.org/10.1016/S0140-6736(09)61526-9
  9. Chollat-Traquet C (1992). Women and tobacco, world health organization, Geneva pp. 8, 203.
  10. De Perrot M, Licker M, Bouchardy C, et al (2000). Sex differences in presentation, management, and prognosis of patients with nonsmall cell lung carcinoma. J Thorac Cardiovasc Surg, 119, 21-6. https://doi.org/10.1016/S0022-5223(00)70213-3
  11. Deleuran T, Thomsen RW, Norgaard M, et al (2013). Comorbidity and survival of danish lung cancer patients from 2000-2011: a population-based cohort study. Clin Epidemiol, 1, 31-8.
  12. Devesa SS, Bray F, Vizcaino AP, Parkin DM (2005). International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer, 117, 294-9 https://doi.org/10.1002/ijc.21183
  13. Dresler C, Fratelli C, Babb J, et al (2000). Gender differences in genetic susceptibility to lung cancer. Lung Cancer, 30, 153-60. https://doi.org/10.1016/S0169-5002(00)00163-X
  14. Efficace F, Bottomley A, Smit EF, et al (2006). EORTC lung cancer group quality of life unit. is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? a multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol, 17, 1698-704. https://doi.org/10.1093/annonc/mdl183
  15. Ferrigno D, Buccheri G (2003). Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients. Monaldi Arch Chest Dis, 59, 193-8.
  16. Finkelstein DM, Ettinger DS, Ruckdeschel JC (1986). Longterm survivors in metastatic non-small cell lung cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol, 4, 702-09.
  17. Gasperina J, Rom W (2004). Gender and lung cancer. Clin Lung Cancer, 5, 353-9. https://doi.org/10.3816/CLC.2004.n.013
  18. Goksel T, Akkoclu A (2002). Pattern of lung cancer in Turkey, 1994-1998. Turkish Thoracic Society, Lung and Pleural Malignancies Study Group. Respiration, 69, 207-10. https://doi.org/10.1159/000063621
  19. Gonlugur U, Gonlugur TE, Kaptanoglu M, et al (2008). The changing epidemiological trends for carcinoma of the lung in Turkey. Saudi Med J, 29, 749-53.
  20. Nakamura H, Ando K, Shinmyo T, et al (2011). Female gender is an independent prognostic factor in non-small cell lung cancer: a meta-analysis. Ann Thorac Cardiovasc Surg, 17, 469-80. https://doi.org/10.5761/atcs.oa.10.01637
  21. Henschke CI, Yip R, Miettinen OS (2006). Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA, 296, 180-4. https://doi.org/10.1001/jama.296.2.180
  22. Kawai H, Tada A, Kawahara M, et al (2005). Japan national hospital study group for lung cancer. smoking history before surgery and prognosis in patients with stage IA non-small cell lung cancer-a multicenter study. Lung Cancer, 49, 63-70. https://doi.org/10.1016/j.lungcan.2004.12.006
  23. Keller SM, Vangel MG, Adak S, et al (2002). The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. Lung Cancer, 37, 303-9. https://doi.org/10.1016/S0169-5002(02)00103-4
  24. Koyi H, Hillerdal G, Branden E (2002). A prospective study of total material of lung cancer from a county in Sweden 1997-1999; gender, symptoms, type, stage and smoking habits. Lung Cancer, 36, 9-14. https://doi.org/10.1016/S0169-5002(01)00451-2
  25. Kure EH, Ryberg D, Hewer A et al (1996). P53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis, 17, 2201-5. https://doi.org/10.1093/carcin/17.10.2201
  26. Miller VA, Kris MG, Shah N, et al (2004). Bronchiolo-alveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol, 22, 1103-9. https://doi.org/10.1200/JCO.2004.08.158
  27. Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57. https://doi.org/10.1056/NEJMoa0810699
  28. Mostertz W, Stevenson M, Acharya C, et al (2010). Age-and sex-specific genomic profiles in non-small cell lung cancer. JAMA, 303, 535-43. https://doi.org/10.1001/jama.2010.80
  29. North CM, Christiani DC (2013). Women and lung cancer: what is new? Semin Thorac Cardiovasc Surg, 25, 87-94. https://doi.org/10.1053/j.semtcvs.2013.05.002
  30. Paesmans M, Sculier JP, Libert P, et al (1995). Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol, 13, 1221-30.
  31. Parente Lamelas I, Abal Arca J, Garcia Garcia MJ, et al (2011). Lung cancer in women: a comparison with men and an analysis of cases diagnosed in Ourense (Spain) 1999-2006. Arch Bronconeumol, 47, 61-5.
  32. Patel J (2005). Lung cancer in women. J Clin Oncol, 23, 3212-8. https://doi.org/10.1200/JCO.2005.11.486
  33. Pinsky PF, Church TR, Izmirlian G, Kramer BS (2013). The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer, 119, 3976-83. https://doi.org/10.1002/cncr.28326
  34. Pitz MW, Musto G, Navaratnam S (2013). Sex as an independent prognostic factor in a population based, non-small cell lung cancer cohort. Can Respir J, 20, 30-4. https://doi.org/10.1155/2013/618691
  35. Radzikowska E, Glaz P, Roszkowski K (2002). Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20, 561 cases. Ann Oncol, 13, 1087-93. https://doi.org/10.1093/annonc/mdf187
  36. Risch HA, Howe GR, Jain M, et al (1993). Are female smokers at higher risk for lung cancer than male smokers? A casecontrol analysis by histologic type. Am J Epidemiol, 138, 281-93.
  37. Sculier JP, Chansky K, Crowley JJ, et al (2008). International staging committee participating institutions. the impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol, 3, 457-66. https://doi.org/10.1097/JTO.0b013e31816de2b8
  38. Sekine A, Satoh H, Iwasawa T, et al (2014). Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy. Med Oncol, 3, 228-34.
  39. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32. https://doi.org/10.1056/NEJMoa050753
  40. Shriver SP , Bourdeau HA, Gubish CT, et al. (2000). Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J Natl Cancer Inst, 92, 24-33. https://doi.org/10.1093/jnci/92.1.24
  41. Siegel R, Ma J, Zou Z, Jemal A (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29. https://doi.org/10.3322/caac.21208
  42. Subramanian J, Morgensztern D, Goodgame B, et al. (2010). Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. J Thorac Oncol, 5, 23-8. https://doi.org/10.1097/JTO.0b013e3181c41e8d
  43. Sun S, Schiller JH, Gazdar AK (2007). Lung cancer in never smokers-a different disease. Nat Rev Cancer, 7, 778-90. https://doi.org/10.1038/nrc2190
  44. Taioli E, Wynder EL (1994). Re: endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst, 86, 869-70. https://doi.org/10.1093/jnci/86.11.869
  45. Thomas L, Doyle L, Edelman M (2005). Lung cancer in women: emerging differences in epidemiology, biology and therapy. Chest, 128, 370-81. https://doi.org/10.1378/chest.128.1.370
  46. Travis WD, Brambilla E, Muller-Hermlink HK, Harris CC (eds). (2004). World health organization classification of tumours. pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon.
  47. Travis WD, Lubin J, Ries L, Devesa S (1996). United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer, 77, 2464-70. https://doi.org/10.1002/(SICI)1097-0142(19960615)77:12<2464::AID-CNCR8>3.0.CO;2-M
  48. Visbal AL, Williams BA, Nichols FC 3rd, et al (2004). Gender differences in non-small cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg, 78, 209-15. https://doi.org/10.1016/j.athoracsur.2003.11.021
  49. Wakelee HA, Chang ET, Gomez SL, et al (2007). Lung cancer incidence in never smokers. J Clin Oncol, 25, 472-8. https://doi.org/10.1200/JCO.2006.07.2983
  50. Wakelee HA, Wang W, Schiller JH, et al (2006). Eastern Cooperative Oncology Group. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol, 1, 441-6. https://doi.org/10.1097/01243894-200606000-00011
  51. Wheatley-Price P, Blackhall F, Lee SM, et al (2010). The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol, 21, 2023-8. https://doi.org/10.1093/annonc/mdq067
  52. Yang SY, Yang TY, Chen KC, et al (2011). EGFR L858R mutation and polymorphisms of genes related to estrogen biosynthesis and metabolism in never-smoking female lung adenocarcinoma patients. Clin Cancer Res, 17, 2149-58. https://doi.org/10.1158/1078-0432.CCR-10-2045
  53. Yano T, Miura N, Takenaka T, et al (2008). Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival. Cancer, 113, 1012-8. https://doi.org/10.1002/cncr.23679
  54. Yoshino I, Kawano D, Oba T, et al 2006). Smoking status as a prognostic factor in patients with stage I pulmonary adenocarcinoma. Ann Thorac Surg, 81, 1189-93. https://doi.org/10.1016/j.athoracsur.2005.09.028

Cited by

  1. Women and Tobacco Use: Discrepancy in the Knowledge, Belief and Behavior towards Tobacco Consumption among Urban and Rural Women in Chhattisgarh, Central India vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6365
  2. Differences in cancer survival by sex: a population-based study using cancer registry data pp.1573-7225, 2018, https://doi.org/10.1007/s10552-018-1079-z